相关实验视频

Updated: Jun 11, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

佛萨普雷皮坦改善了循环胺诱导的膀损伤,通过减轻小鼠的炎症反应

Yaren Yesilbas Aksel¹, Elif Nur Barut², Seckin Engin²

¹Karadeniz Technical University, Graduate School of Health Sciences, Department of Pharmacology, Türkiye.

Toxicology and applied pharmacology

|October 8, 2024

概括

福萨普雷皮坦 (FOS),一种神经素1受体对手,在循环胺诱导的囊炎模型中有效降低了炎症并改善了膀功能. 这项研究强调了FOS作为通过向炎症通路来治疗间歇性囊炎的潜在治疗方法.

科学领域:

药理学药理学是指药理学的学科.
泌尿器科泌尿器科泌尿器科泌尿器科
免疫学免疫学免疫学

背景情况:

间歇性囊炎 (IC) 涉及显著的炎症,使抗炎策略对治疗至关重要.
神经素1受体 (NK1R) 抗剂在治疗炎症状况方面表现有前途.
环胺 (CP) 诱导的囊炎作为研究IC的相关临床前模型.

研究的目的:

研究NK1R抗剂fosaprepitant (FOS) 对循环胺 (CP) 诱导的囊炎的保护作用.
在小鼠膀炎症模型中评估FOS对体收缩性,血管透性和炎症标志物的影响.

主要方法:

一个小鼠模型的囊炎被诱导使用多次注射环胺 (CP).
小鼠在连续七天内通过腹腔内接种不同剂量的前 (FOS).
评估的参数包括detrusor肌肉收缩性,膀血管透性,髓氧化酶 (MPO) 活性和Toll-like受体4 (TLR4) 通路表达.

主要成果:

FOS治疗显著减弱了在CP诱导的囊炎中观察到的增加的dtrusor收缩性.
施用FOS恢复了膀血管透能力受损,并明显抑制了膀组织中MPO活性升高.
FOS治疗显著降低了TLR4表达,这表明通过抑制关键炎症途径,具有抗炎作用.

结论:

佛萨普雷皮坦在间歇性囊炎的临床前模型中显示出显著的保护作用.
通过抑制MPO活性和TLR4表达,FOS可以改善dtrusor过度活动并减少炎症.
这些发现表明,FOS具有作为治疗干膜炎和相关的炎症性膀疾病管理的治疗剂的潜力.

关键词:

囊炎是一种囊炎.破坏者过度活动.炎症炎症是一种炎症.神经基因素1受体是什么?收费像受体4的收费方式

更多相关视频

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Transurethral Instillation Procedure in Adult Male Mouse

Transurethral Instillation Procedure in Adult Male Mouse

Published on: November 2, 2017

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...